REG - Haleon PLC GSK PLC - Holding(s) in Company
18/07/2022 18:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220718:nRSR8809Sa&default-theme=true
RNS Number : 8809S Haleon PLC 18 July 2022
Haleon plc
TR-1: Notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the
FCA in Microsoft Word format if possible) (i)
1a. Identity of the issuer or the underlying issuer of existing shares to Haleon plc
which voting rights are attached (ii):
1b. Please indicate if the issuer is a non-UK issuer (please mark with an
"X" if appropriate)
Non-UK issuer
2. Reason for the notification (please mark the appropriate box or boxes with
an "X")
An acquisition or disposal of voting rights X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) (iii):
3. Details of person subject to the notification obligation (iv)
Name GSK plc and the following controlled undertakings of GSK plc: GSK LP Limited,
GSK GP 1 Limited and GSK (No. 1) Scottish Limited Partnership
City and country of registered office (if applicable) London, England (GSK plc and GSK LP Limited) and Edinburgh, Scotland (GSK GP 1
Limited and GSK (No. 1) Scottish Limited Partnership)
4. Full name of shareholder(s) (if different from 3.) (v)
Name Vidacos Nominees Limited
City and country of registered office (if applicable) London, England
5. Date on which the threshold was crossed or reached (vi): 18 July 2022
6. Date on which issuer notified (DD/MM/YYYY): 18/07/2022
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments Total of both in % (8.A + 8.B) Total number of voting rights held in issuer (8.A + 8.B) (vii)
(total of 8.B 1 + 8.B 2)
Resulting situation on the date on which threshold was crossed or reached 12.94 0 12.94 1,195,320,110
Position of previous notification (if N/A N/A N/A
applicable)
8. Notified details of the resulting situation on the date on which the
threshold was crossed or reached (viii)
A: Voting rights attached to shares
Class/type of Number of voting rights (ix) % of voting rights
shares
ISIN code (if possible)
Direct Indirect Direct Ind
ire
(DTR5.1) (DTR5.2.1) (DTR5.1) ct
(DT
R5.
2.1
)
GB00BMX86B70 502,727,073 692,593,037 5.44 7.50
SUBTOTAL 8. A 1,195,320,110 12.94
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument Expiration Exercise/ Number of voting rights that may be acquired if the instrument is % of voting rights
date (x)
Conversion Period (xi)
exercised/converted.
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R
(1) (b)
Type of financial instrument Expiration Exercise/ Physical or cash Number of voting rights % of voting rights
date (x)
Conversion Period (xi)
Settlement (xii)
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification
obligation (please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural
person or legal entity and does not control any other undertaking(s) holding
directly or indirectly an interest in the (underlying) issuer (xiii)
Full chain of controlled undertakings through which the voting rights and/or X
the
financial instruments are effectively held starting with the ultimate
controlling natural person or legal entity (please add additional rows as
necessary) (xiv)
Name (xv) % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher Total of both if it equals or is higher than the notifiable threshold
than the notifiable threshold
GSK plc (direct holding) 5.44 5.44
GSK plc (Chain 1) 4.74 4.74
GSK LP Limited (Chain 1) 4.74 4.74
GSK GP 1 Limited (Chain 1) 4.74 4.74
GSK (No. 1) Scottish Limited Partnership (Chain 1) 4.74 4.74
GSK plc (Chain 2) 1.78 1.78
GSK LP Limited (Chain 2) 1.78 1.78
GSK GP 1 Limited (Chain 2) 1.78 1.78
GSK (No. 2) Scottish Limited Partnership (Chain 2) 1.78 1.78
GSK plc (Chain 3) 0.98 0.98
GSK LP Limited (Chain 3) 0.98 0.98
GSK GP 2 Limited (Chain 3) 0.98 0.98
GSK (No. 3) Scottish Limited Partnership (Chain 3) 0.98 0.98
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information (xvi)
GSK plc is making this notification on behalf of itself and on behalf of GSK
LP Limited, GSK GP 1 Limited and GSK (No. 1) Scottish Limited Partnership.
GSK plc, GSK (No. 1) Scottish Limited Partnership, GSK (No. 2) Scottish
Limited Partnership and GSK (No. 3) Scottish Limited Partnership hold their
shares in Haleon plc via a custodian, Vidacos Nominees Limited (as detailed in
section 4 above), which holds the legal title to those shares on their behalf
pursuant to a custody arrangement.
These calculations are based on an issued share capital of Haleon plc of
9,234,573,831 ordinary shares.
Place of completion London, England
Date of completion 18 July 2022
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END HOLUWVNRUUUBAARRecent news on GSK
See all newsREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Total Voting Rights
AnnouncementREG - GSK PLC - 1st Quarter Results
AnnouncementREG - GSK PLC - US FDA accepts new indication filing for Jemperli
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
Announcement